Ratings Bavarian Nordic A/S

Equities

BAVA

DK0015998017

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:49 2024-04-18 am EDT			5-day change	1st Jan Change
146.8 ^DKK	-1.51%		-3.23%	-17.30%

Mar. 13	Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	MT
Mar. 13	Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BAVARIAN NORDIC A/S	-17.30%	1.66B	B
ELI LILLY AND COMPANY	+27.97%	676B	C+
NOVO NORDISK A/S	+23.58%	554B	B
JOHNSON & JOHNSON	-7.02%	349B	C+
MERCK & CO., INC.	+14.85%	318B	B-
ABBVIE INC.	+6.25%	291B	C+
ASTRAZENECA PLC	+2.96%	210B	B+
NOVARTIS AG	-0.41%	204B	B-
ROCHE HOLDING AG	-10.02%	194B	A+
PFIZER, INC.	-11.81%	144B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes